SVF
Level A· Stronger Clinical EvidenceSystematic Review

Limited evidence for adipose-derived stem cell therapy on the treatment of osteoarthritis.

Hurley ET., Yasui Y., Gianakos AL., Seow D., Shimozono Y., Kerkhoffs GMMJ.

Systematic Review on Osteoarthritis, Ankle Injury, published in Knee Surg Sports Traumatol Arthrosc (2018) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Knee Surg Sports Traumatol Arthrosc (2018)
Country
Germany
Reported sample size
—
PMID
29713784
DOI
10.1007/s00167-018-4955-x

Abstract (original English)

The purpose of this systematic review is to evaluate the effects of adipose derived mesenchymal stem cells (ADSCs) in the treatment of osteoarthritis (OA) in the clinical setting. A literature search was performed in the MEDLINE, EMBASE, and The Cochrane Library Database up to January 2017 for inclusion and exclusion criteria. Criteria for inclusion were clinical studies demonstrating the effects of ADSCs on OA, and written in English. The following variables were analyzed: donor site, volume of adipose tissue, preparation of ADSCs, clinical outcomes, and complication rate. Sixteen studies (knee: 14 studies, multiple joints: 1 study, ankle: 1 study) were included in this systematic review. All of the studies prepared ADSCs in the form of the stromal vascular fraction (SVF). Inconsistencies between studies were found with regards to reported clinical variability, donor sites of SVF, and reported clinical outcomes. Nine studies used either platelet-rich plasma (PRP) (7/16) or fibrin (4/16) or both PRP and Fibrin (1/16), as an adjunct at time of SVF injection. All of the studies reported an improvement in clinical outcomes with the use of SVF. Five studies reported a 90% satisfaction rate, and no study reported any complications with liposuction. Five studies reported on complications, with a 5% incidence of swelling and pain. This systematic review demonstrated that ADSCs are cur

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Adipose TissueFibrinHumansOsteoarthritisPlatelet-Rich PlasmaStem Cell Transplantation
KneeAnkle & FootOsteoarthritisAnkle Injury
View on PubMedDOI

Related research